Management of Chronic Low Back Pain in Older Adults Using Auricular Point Acupressure
NCT03589703, Not applicable, Completed, The University of Texas Health Science Center, Houston; results first posted 2024-04-24
Trial 11
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Management of Chronic Low Back Pain in Older Adults Using Auricular Point Acupressure | ClinicalTrials.gov |
| NCT number | NCT03589703 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 272 participants, actual | ClinicalTrials.gov |
| Lead sponsor | The University of Texas Health Science Center, Houston | ClinicalTrials.gov |
| Conditions | Chronic Low Back Pain | ClinicalTrials.gov |
| Interventions | Target ear points related to chronic low back pain (T-APA), Non-Target ear Points not related to chronic low back pain (NT-APA), Enhanced Educational Control Group (CG-2) | ClinicalTrials.gov |
| First posted | 2018-07-18 | ClinicalTrials.gov |
| Last updated | 2024-04-24 | ClinicalTrials.gov |
| Results first posted | 2024-04-24 | ClinicalTrials.gov |
Registered outcomes 24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Pain Intensity as Assessed by the Numeric Rating Scale (NRS) | Baseline | Pain intensity as assessed by the NRS for worst pain in the past 7 days using a 0-10 scale (0 = "no pain" and 10 = "worst pain imaginable") | ClinicalTrials.gov |
| Primary | Pain Intensity as Assessed by the Numeric Rating Scale (NRS) | 1 month post completion of the treatment (2 months after baseline) | Pain intensity as assessed by the NRS for worst pain in the past 7 days using a 0-10 scale (0 = "no pain" and 10 = "worst pain imaginable") | ClinicalTrials.gov |
| Primary | Pain Interference as Assessed by the Brief Pain Inventory-short Form Pain Interference Subscale | Baseline | Pain interference is assessed by the Brief Pain Inventory pain interference subscale, which uses a 0-10 scale (0 = "does not interfere" and 10 = "completely interferes"). | ClinicalTrials.gov |
| Primary | Pain Interference as Assessed by the Brief Pain Inventory-short Form Pain Interference Subscale | 1 month post completion of the treatment (2 months after baseline) | Pain interference is assessed by the Brief Pain Inventory pain interference subscale, which uses a 0-10 scale (0 = "does not interfere" and 10 = "completely interferes"). | ClinicalTrials.gov |
| Primary | Physical Function as Assessed by the Roland Morris Disability Questionnaire (RMDQ) | Baseline | The Roland Morris Disability Questionnaire (RMDQ), 24-item measure, is used to assess the impact of back pain on their daily functioning. The score ranges from 0 (no disability) to 24 (maximum disability). | ClinicalTrials.gov |
| Primary | Physical Function as Assessed by the Roland Morris Disability Questionnaire (RMDQ) | 1 month post completion of the treatment (2 months after baseline) | The Roland Morris Disability Questionnaire (RMDQ), 24-item measure, is used to assess the impact of back pain on their daily functioning. The score ranges from 0 (no disability) to 24 (maximum disability). | ClinicalTrials.gov |
| Secondary | Number of Participants Who Use Opioids | Baseline | ClinicalTrials.gov | |
| Secondary | Number of Participants Who Use Opioids | 1 month post completion of the treatment (2 months after baseline) | ClinicalTrials.gov | |
| Secondary | APA Treatment Satisfaction as Assessed by Satisfaction Survey | immediately post intervention (1 month after baseline) | Satisfaction is assessed using a 5-point numeric rating scale: 1. \- Completely satisfied 2. \- Somewhat satisfied 3. \- Neither satisfied nor dissatisfied 4. \- Somewhat dissatisfied 5. \- Very dissatisfied | ClinicalTrials.gov |
| Secondary | APA Treatment Satisfaction as Assessed by Satisfaction Survey | 1 month post completion of the treatment (2 months after baseline) | Satisfaction is assessed using a 5-point numeric rating scale: 1. \- Completely satisfied 2. \- Somewhat satisfied 3. \- Neither satisfied nor dissatisfied 4. \- Somewhat dissatisfied 5. \- Very dissatisfied | ClinicalTrials.gov |
| Secondary | Quality of Life as Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS-29) - Anxiety | Baseline | The Patient-Reported Outcomes Measurement Information System (PROMIS-29) is a 29-item profile instrument that can be used to assess seven subscales of health quality of life (QOL) for each of 7 domains-this outcome measure reports one of the 7 domains, anxiety. The raw score on the anxiety subscale is converted to a standardized T-score. T-score is reported here, and it ranges from 0 to 100, with a higher PROMIS T-score representing more of the concept being measured, that is, greater anxiety. PROMIS uses a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population; therefore, an anxiety T-score of 40 is one SD better than average in terms of anxiety. A T-score below 55 is indicative of anxiety within normal limits. | ClinicalTrials.gov |
| Secondary | Quality of Life as Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS-29) - Anxiety | 1 month post completion of the treatment (2 months after baseline) | The Patient-Reported Outcomes Measurement Information System (PROMIS-29) is a 29-item profile instrument that can be used to assess seven subscales of health quality of life (QOL) for each of 7 domains-this outcome measure reports one of the 7 domains, anxiety. The raw score on the anxiety subscale is converted to a standardized T-score. T-score is reported here, and it ranges from 0 to 100, with a higher PROMIS T-score representing more of the concept being measured, that is, greater anxiety. PROMIS uses a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population; therefore, an anxiety T-score of 40 is one SD better than average in terms of anxiety. A T-score below 55 is indicative of anxiety within normal limits. | ClinicalTrials.gov |
| Secondary | Quality of Life as Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS-29) - Depression | Baseline | The Patient-Reported Outcomes Measurement Information System (PROMIS-29) is a 29-item profile instrument that can be used to assess seven subscales of health quality of life (QOL) for each of 7 domains-this outcome measure reports one of the 7 domains, depression. The raw score on the depression subscale is converted to a standardized T-score. T-score is reported here, and it ranges from 0 to 100, with a higher PROMIS T-score representing more of the concept being measured, that is, greater depression. PROMIS uses a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population; therefore, a depression T-score of 40 is one SD better than average in terms of depression. A T-score below 55 is indicative of depression within normal limits. | ClinicalTrials.gov |
| Secondary | Quality of Life as Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS-29) - Depression | 1 month post completion of the treatment (2 months after baseline) | The Patient-Reported Outcomes Measurement Information System (PROMIS-29) is a 29-item profile instrument that can be used to assess seven subscales of health quality of life (QOL) for each of 7 domains-this outcome measure reports one of the 7 domains, depression. The raw score on the depression subscale is converted to a standardized T-score. T-score is reported here, and it ranges from 0 to 100, with a higher PROMIS T-score representing more of the concept being measured, that is, greater depression. PROMIS uses a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population; therefore, a depression T-score of 40 is one SD better than average in terms of depression. A T-score below 55 is indicative of depression within normal limits. | ClinicalTrials.gov |
| Secondary | Quality of Life as Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS-29) - Sleep Disturbance | Baseline | The Patient-Reported Outcomes Measurement Information System (PROMIS-29) is a 29-item profile instrument that can be used to assess seven subscales of health quality of life (QOL) for each of 7 domains-this outcome measure reports one of the 7 domains, sleep disturbance. The raw score on the sleep disturbance subscale is converted to a standardized T-score. T-score is reported here, and it ranges from 0 to 100, with a higher PROMIS T-score representing more of the concept being measured, that is, greater sleep disturbance. PROMIS uses a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population; therefore, a sleep disturbance T-score of 40 is one SD better than average in terms of sleep disturbance. A T-score below 55 is indicative of sleep disturbance within normal limits. | ClinicalTrials.gov |
| Secondary | Quality of Life as Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS-29) - Sleep Disturbance | 1 month post completion of the treatment (2 months after baseline) | The Patient-Reported Outcomes Measurement Information System (PROMIS-29) is a 29-item profile instrument that can be used to assess seven subscales of health quality of life (QOL) for each of 7 domains-this outcome measure reports one of the 7 domains, sleep disturbance. The raw score on the sleep disturbance subscale is converted to a standardized T-score. T-score is reported here, and it ranges from 0 to 100, with a higher PROMIS T-score representing more of the concept being measured, that is, greater sleep disturbance. PROMIS uses a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population; therefore, a sleep disturbance T-score of 40 is one SD better than average in terms of sleep disturbance. A T-score below 55 is indicative of sleep disturbance within normal limits. | ClinicalTrials.gov |
| Secondary | Fear-Avoidance as Assessed by the Fear-avoidance Beliefs Questionnaire (FABQ) | Baseline | The fear-avoidance beliefs questionnaire (FABQ) focuses on participant's beliefs about how physical activity and work affect their pain. The questionnaire consists of 16 items in which a participant rates their agreement with each statement on a 7-point Likert scale where 0 = completely disagree and 6 =completely agree. The total score ranges from 0 to 96. A higher score indicates more strongly held fear-avoidance beliefs. | ClinicalTrials.gov |
| Secondary | Fear-Avoidance as Assessed by the Fear-avoidance Beliefs Questionnaire (FABQ) | 1 month post completion of the treatment (2 months after baseline) | The fear-avoidance beliefs questionnaire (FABQ) focuses on participant's beliefs about how physical activity and work affect their pain. The questionnaire consists of 16 items in which a participant rates their agreement with each statement on a 7-point Likert scale where 0 = completely disagree and 6 =completely agree. The total score ranges from 0 to 96. A higher score indicates more strongly held fear-avoidance beliefs. | ClinicalTrials.gov |
| Secondary | Pain Catastrophizing as Assessed by the Pain Catastrophizing Scale (PCS) | Baseline | The PCS was included to detect exaggerated and negative interpretations of pain. It is a self-report scale that consists of13 items. Participants were asked to reflect on past painful experiences and to indicate to which degree he/she experienced symptoms such as helplessness or rumination when feeling pain. This is a 0-4 Likert scale (score sum 0-52) with responses ranging from "not at all" to "all the time," with higher scores indicate stronger catastrophizing. | ClinicalTrials.gov |
| Secondary | Pain Catastrophizing as Assessed by the Pain Catastrophizing Scale (PCS) | 1 month post completion of the treatment (2 months after baseline) | The PCS was included to detect exaggerated and negative interpretations of pain. It is a self-report scale that consists of13 items. Participants were asked to reflect on past painful experiences and to indicate to which degree he/she experienced symptoms such as helplessness or rumination when feeling pain. This is a 0-4 Likert scale (score sum 0-52) with responses ranging from "not at all" to "all the time," with higher scores indicate stronger catastrophizing. | ClinicalTrials.gov |
Outcomes 24
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|---|---|---|---|---|---|
| PRIMARY | Pain Intensity as Assessed by the Numeric Rating Scale (NRS) | Baseline | score on a scale | MEAN | ClinicalTrials.gov | |
| PRIMARY | Pain Intensity as Assessed by the Numeric Rating Scale (NRS) | 1 month post completion of the treatment (2 months after baseline) | Data were not collected for 11 in the T-APA arm, 19 in the NT-APA arm, and 20 in the Control arm. | score on a scale | MEAN | ClinicalTrials.gov |
| PRIMARY | Pain Interference as Assessed by the Brief Pain Inventory-short Form Pain Interference Subscale | Baseline | score on a scale | MEAN | ClinicalTrials.gov | |
| PRIMARY | Pain Interference as Assessed by the Brief Pain Inventory-short Form Pain Interference Subscale | 1 month post completion of the treatment (2 months after baseline) | Data were not collected for 11 in the T-APA arm, 19 in the NT-APA arm, and 20 in the Control arm. | score on a scale | MEAN | ClinicalTrials.gov |
| PRIMARY | Physical Function as Assessed by the Roland Morris Disability Questionnaire (RMDQ) | Baseline | score on a scale | MEAN | ClinicalTrials.gov | |
| PRIMARY | Physical Function as Assessed by the Roland Morris Disability Questionnaire (RMDQ) | 1 month post completion of the treatment (2 months after baseline) | Data were not collected for 11 in the T-APA arm, 19 in the NT-APA arm, and 18 in the Control arm. | score on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | Number of Participants Who Use Opioids | Baseline | Participants | COUNT_OF_PARTICIPANTS | ClinicalTrials.gov | |
| SECONDARY | Number of Participants Who Use Opioids | 1 month post completion of the treatment (2 months after baseline) | Data were not collected for 17 in the T-APA arm, 29 in the NT-APA arm, and 20 in the control arm. | Participants | COUNT_OF_PARTICIPANTS | ClinicalTrials.gov |
| SECONDARY | APA Treatment Satisfaction as Assessed by Satisfaction Survey | immediately post intervention (1 month after baseline) | Data were not collected for 11 in the T-APA arm and 17 in the NT-APA arm. These data were not collected for any of the 89 in the control arm, as they did not receive the APA treatment. | score on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | APA Treatment Satisfaction as Assessed by Satisfaction Survey | 1 month post completion of the treatment (2 months after baseline) | Data were not collected for 17 in the T-APA arm and 29 in the NT-APA arm. These data were not collected for any of the 89 in the control arm, as they did not receive the APA treatment. | score on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | Quality of Life as Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS-29) - Anxiety | Baseline | T-score | MEAN | ClinicalTrials.gov | |
| SECONDARY | Quality of Life as Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS-29) - Anxiety | 1 month post completion of the treatment (2 months after baseline) | Data were not collected for 11 in the T-APA arm, 19 in the NT-APA arm, and 20 in the Control arm. | T-score | MEAN | ClinicalTrials.gov |
| SECONDARY | Quality of Life as Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS-29) - Depression | Baseline | T-score | MEAN | ClinicalTrials.gov | |
| SECONDARY | Quality of Life as Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS-29) - Depression | 1 month post completion of the treatment (2 months after baseline) | Data were not collected for 11 in the T-APA arm, 19 in the NT-APA arm, and 20 in the Control arm. | T-score | MEAN | ClinicalTrials.gov |
| SECONDARY | Quality of Life as Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS-29) - Sleep Disturbance | Baseline | T-score | MEAN | ClinicalTrials.gov | |
| SECONDARY | Quality of Life as Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS-29) - Sleep Disturbance | 1 month post completion of the treatment (2 months after baseline) | Data were not collected for 11 in the T-APA arm, 19 in the NT-APA arm, and 20 in the Control arm. | T-score | MEAN | ClinicalTrials.gov |
| SECONDARY | Fear-Avoidance as Assessed by the Fear-avoidance Beliefs Questionnaire (FABQ) | Baseline | score on a scale | MEAN | ClinicalTrials.gov | |
| SECONDARY | Fear-Avoidance as Assessed by the Fear-avoidance Beliefs Questionnaire (FABQ) | 1 month post completion of the treatment (2 months after baseline) | Data were not collected for 11 in the T-APA arm, 29 in the NT-APA arm, and 21 in the Control arm. | score on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | Pain Catastrophizing as Assessed by the Pain Catastrophizing Scale (PCS) | Baseline | score on a scale | MEAN | ClinicalTrials.gov | |
| SECONDARY | Pain Catastrophizing as Assessed by the Pain Catastrophizing Scale (PCS) | 1 month post completion of the treatment (2 months after baseline) | Data were not collected for 11 in the T-APA arm, 19 in the NT-APA arm, and 21 in the Control arm. | score on a scale | MEAN | ClinicalTrials.gov |
Results by group 58
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|---|---|---|---|---|---|
| Pain Intensity as Assessed by the Numeric Rating Scale (NRS) | T-APA | 7.4 | Standard Deviation 1.7 | score on a scale | ClinicalTrials.gov | |
| Pain Intensity as Assessed by the Numeric Rating Scale (NRS) | NT-APA | 7.0 | Standard Deviation 1.8 | score on a scale | ClinicalTrials.gov | |
| Pain Intensity as Assessed by the Numeric Rating Scale (NRS) | Enhanced Educational Control Group (CG-2) | 7.3 | Standard Deviation 1.7 | score on a scale | ClinicalTrials.gov | |
| Pain Intensity as Assessed by the Numeric Rating Scale (NRS) | T-APA | 5.6 | Standard Deviation 2.7 | score on a scale | ClinicalTrials.gov | |
| Pain Intensity as Assessed by the Numeric Rating Scale (NRS) | NT-APA | 5.3 | Standard Deviation 2.7 | score on a scale | ClinicalTrials.gov | |
| Pain Intensity as Assessed by the Numeric Rating Scale (NRS) | Enhanced Educational Control Group (CG-2) | 6.6 | Standard Deviation 2.2 | score on a scale | ClinicalTrials.gov | |
| Pain Interference as Assessed by the Brief Pain Inventory-short Form Pain Interference Subscale | T-APA | 3.2 | Standard Deviation 1.7 | score on a scale | ClinicalTrials.gov | |
| Pain Interference as Assessed by the Brief Pain Inventory-short Form Pain Interference Subscale | NT-APA | 3.3 | Standard Deviation 1.7 | score on a scale | ClinicalTrials.gov | |
| Pain Interference as Assessed by the Brief Pain Inventory-short Form Pain Interference Subscale | Enhanced Educational Control Group (CG-2) | 3.1 | Standard Deviation 1.6 | score on a scale | ClinicalTrials.gov | |
| Pain Interference as Assessed by the Brief Pain Inventory-short Form Pain Interference Subscale | T-APA | 2.7 | Standard Deviation 1.9 | score on a scale | ClinicalTrials.gov | |
| Pain Interference as Assessed by the Brief Pain Inventory-short Form Pain Interference Subscale | NT-APA | 2.5 | Standard Deviation 1.6 | score on a scale | ClinicalTrials.gov | |
| Pain Interference as Assessed by the Brief Pain Inventory-short Form Pain Interference Subscale | Enhanced Educational Control Group (CG-2) | 2.9 | Standard Deviation 1.7 | score on a scale | ClinicalTrials.gov | |
| Physical Function as Assessed by the Roland Morris Disability Questionnaire (RMDQ) | T-APA | 12.4 | Standard Deviation 5.3 | score on a scale | ClinicalTrials.gov | |
| Physical Function as Assessed by the Roland Morris Disability Questionnaire (RMDQ) | NT-APA | 12.6 | Standard Deviation 6.2 | score on a scale | ClinicalTrials.gov | |
| Physical Function as Assessed by the Roland Morris Disability Questionnaire (RMDQ) | Enhanced Educational Control Group (CG-2) | 12.0 | Standard Deviation 5.9 | score on a scale | ClinicalTrials.gov | |
| Physical Function as Assessed by the Roland Morris Disability Questionnaire (RMDQ) | T-APA | 9.8 | Standard Deviation 6.2 | score on a scale | ClinicalTrials.gov | |
| Physical Function as Assessed by the Roland Morris Disability Questionnaire (RMDQ) | NT-APA | 9.6 | Standard Deviation 6.6 | score on a scale | ClinicalTrials.gov | |
| Physical Function as Assessed by the Roland Morris Disability Questionnaire (RMDQ) | Enhanced Educational Control Group (CG-2) | 10.5 | Standard Deviation 5.8 | score on a scale | ClinicalTrials.gov | |
| Number of Participants Who Use Opioids | T-APA | 44 | Participants | ClinicalTrials.gov | ||
| Number of Participants Who Use Opioids | NT-APA | 45 | Participants | ClinicalTrials.gov |
Participant flow 12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|---|---|---|---|---|
| Overall Study | STARTED | T-APA | 92 | ClinicalTrials.gov | |
| Overall Study | STARTED | NT-APA | 91 | ClinicalTrials.gov | |
| Overall Study | STARTED | Enhanced Educational Control Group (CG-2) | 89 | ClinicalTrials.gov | |
| Overall Study | Completed Follow up 1 Month Post-intervention | T-APA | 81 | ClinicalTrials.gov | |
| Overall Study | Completed Follow up 1 Month Post-intervention | NT-APA | 68 | ClinicalTrials.gov | |
| Overall Study | Completed Follow up 1 Month Post-intervention | Enhanced Educational Control Group (CG-2) | 71 | ClinicalTrials.gov | |
| Overall Study | COMPLETED | T-APA | 81 | ClinicalTrials.gov | |
| Overall Study | COMPLETED | NT-APA | 68 | ClinicalTrials.gov | |
| Overall Study | COMPLETED | Enhanced Educational Control Group (CG-2) | 71 | ClinicalTrials.gov | |
| Overall Study | NOT COMPLETED | T-APA | 11 | ClinicalTrials.gov | |
| Overall Study | NOT COMPLETED | NT-APA | 23 | ClinicalTrials.gov | |
| Overall Study | NOT COMPLETED | Enhanced Educational Control Group (CG-2) | 18 | ClinicalTrials.gov |
Adverse events 3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|---|---|---|---|---|---|---|
| other | Itching/Discomfort on the ear where the seed was placed | General disorders | T-APA | 69 | 92 | 183 | ClinicalTrials.gov |
| other | Itching/Discomfort on the ear where the seed was placed | General disorders | NT-APA | 48 | 91 | 112 | ClinicalTrials.gov |
| other | Itching/Discomfort on the ear where the seed was placed | General disorders | Enhanced Educational Control Group (CG-2) | 0 | 89 | 0 | ClinicalTrials.gov |
Adverse event totals 9
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|---|---|---|---|
| Total, all-cause mortality | T-APA | 0 | 92 | ClinicalTrials.gov |
| Total, all-cause mortality | NT-APA | 0 | 91 | ClinicalTrials.gov |
| Total, all-cause mortality | Enhanced Educational Control Group (CG-2) | 0 | 89 | ClinicalTrials.gov |
| Total, other adverse events | T-APA | 69 | 92 | ClinicalTrials.gov |
| Total, other adverse events | NT-APA | 48 | 91 | ClinicalTrials.gov |
| Total, other adverse events | Enhanced Educational Control Group (CG-2) | 0 | 89 | ClinicalTrials.gov |
| Total, serious adverse events | T-APA | 0 | 92 | ClinicalTrials.gov |
| Total, serious adverse events | NT-APA | 0 | 91 | ClinicalTrials.gov |
| Total, serious adverse events | Enhanced Educational Control Group (CG-2) | 0 | 89 | ClinicalTrials.gov |
Papers 5
The papers the trial lists on ClinicalTrials.gov.
Grants 1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| R01AG056587 | Management of Chronic Low Back Pain in Older Adults Using Auricular Point Acupressure | JOHNSON, CONSTANCE MARGARET; LUKKAHATAI, NADA | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON | NATIONAL INSTITUTE ON AGING | 2018 to 2022 | NIH RePORTER |
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)